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Understanding how peptides are selected for presentation by MHC
class I is crucial to vaccination strategies based on cytotoxic T
lymphocyte priming. We have studied this selection of the MHC
class I peptide repertoire in terms of the presentation of a series of
individual peptides with a wide range of binding to MHC class I.
This series was expressed as minigenes, and the presentation of
each peptide variant was determined with the same MHC class I
peptide-specific antibody. In wild-type cells, the hierarchy of pre-
sentation followed peptide half-life. This hierarchy broke down in
cells lacking tapasin but not in cells lacking calreticulin or in cells
lacking transporter associated with antigen processing-associated
ERp57. We demonstrate a key role for tapasin in shaping the MHC
class I peptide repertoire, as enhancement of presentation in the
presence of tapasin correlated with peptide half-life.
MHC class I molecules may be the ultimate proteomicmicroarray (1). On the surface of a single cell, MHC class
I molecules provide a readout of the expression level of up to
10,000 proteins (2). This array is interpreted by cytotoxic T
lymphocytes and natural killer cells, allowing them to monitor
the events inside the cell and detect infection and tumorigenesis.
MHC class I molecules consist of a complex between heavy
chain, 2-microglobulin (2m), and a peptide of usually 8–11
residues (3). Folding of MHC class I heavy chain in the endo-
plasmic reticulum (ER) is initially assisted by the chaperone
calnexin and ERp57, a thiol-dependent oxidoreductase that
assists disulfide bond formation (4). When 2m associates with
class I heavy chain, calnexin dissociates and class I becomes part
of a peptide loading complex comprising transporter associated
with antigen processing (TAP), tapasin, calreticulin, and ERp57
(5–9). TAP transports peptides from the cytosol into the ER.
Tapasin helps the assembly of class I molecules with peptides
(10). Calreticulin is an ER chaperone for the folding of a wide
variety of glycoproteins. How the proteins in this complex
cooperate in the loading of class I with high-affinity peptide is
unclear. High-affinity peptides are of a length that allows both
their N and C termini to fit in the class I binding groove and have
an allele-specific binding motif (11, 12).
An outstanding problem in the field of antigen presentation is
whether there is catalysis of class I peptide loading, by analogy
to HLA-DM, which edits the peptides bound to MHC class II
according to their binding stability (13). Bulk analysis of class I
does indicate impaired loading either in the absence of tapasin
(5, 14, 15) or with a mutant class I that fails to associate with TAP
(16). This is reflected in lower steady-state levels of class I, faster
decay of class I from the cell surface, and increased export of
peptide-receptive class I to the cell surface. It is unclear whether
this represents class I molecules that are empty or just have a
suboptimal peptide cargo. Attempts to compare the repertoire of
peptides presented with and without tapasin by peptide elution
have failed to detect clear qualitative differences (17–19). Here,
we describe a method to sample the repertoire of peptides
presented at the cell surface and use this method to evaluate the
roles of tapasin, calreticulin, and ERp57 in the loading of class
I with peptide.
Materials and Methods
General Reagents. Peptides were synthesized by using F-moc
chemistry (Peptide Protein Research, Eastleigh, U.K.) and were
95% pure by HPLC and mass spectrometry. Serum-free media
was AIM-V (Sigma).
Antibodies. 25-D1.16 (D1) recognizes H2-Kb-SIINFEKL (20),
kindly provided by R. Germain (National Institutes of Health,
Bethesda). Y3 recognizes a conformation-sensitive epitope of
H2-Kb. 148.3 recognizes human TAP1, kindly provided by R.
Tampe (University of Marburg, Marburg, Germany). Anti-
body to the truncated nerve growth factor receptor (NGFR)
was from the hybridoma 8737 (American Type Culture Col-
lection). Monoclonal antibodies were purified from hybridoma
supernatant on a protein A-Sepharose or protein G-Sepharose
Fast Flow (Amersham Pharmacia) column as appropriate.
Calreticulin expression was determined with the rabbit anti-
Calregulin antiserum C-17 (Santa Cruz Biotechnology).
Cell Lines. Cells were grown in RPMI medium 1640 with 10% FCS
(Globepharm, Surrey, U.K.), 50 unitsml penicillin, 50 gml
streptomycin, and 2 mM glutamine (R10) at 37°C with 5% CO2.
LBL 721.220 (.220) is a human tapasin-deficient B lymphoblastoid
cell line (21). .220 Kb and .220 Kb tapasin were kind gifts of J.
McCluskey (University of Melbourne, Melbourne) (17). Fibroblast
cell lines, from M. Michalak (University of Alberta, Edmonton,
Canada), were generated from wild-type or calreticulin-knockout
mice, as described (22). RMA-S is a TAP-deficient mouse T cell
line.
Plasmids. The retroviral packaging plasmids CMVbipep-NGFR
and CMVbipep-neo have been described (23, 24). Minigene inserts
were generated from primers by PCR for insertion at the SpeI and
MluI sites of CMVbipep-NGFR and encoded the octameric
peptide preceded by methionine, which is cleaved by cytosolic
N-aminopeptidase activity. Wild-type Kb or T134K Kb, a kind gift
of K. Gould (Imperial College London), was subcloned from pKG
into CMVbipep-neo at the XhoI and HincII restriction sites and
introduced into cells with retroviral transduction. NGFR-
expressing cells were purified by using antibody-coated CEL-
Lection Pan Mouse IgG Dynabeads (Dynal, Great Neck, NY).
Neo-expressing cells were selected with 0.5 mgml G418. pBMN-
Zpuro encoding wild-type or C95A human tapasin was a kind gift
of P. Cresswell (Yale University, New Haven, CT). KpnI and
BamHI sites were added to wild-type and C95A tapasin by PCR
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with the primers 5-GTAGGTACCATGAAGTCCCTGTCTCT-
GCTC-3 and 5-GTAGGATCCTCACTCTGCTTTCT-
TCTTTG-3 for subcloning into pREP4, a kind gift of F. Momburg
(German Cancer Research Center, Heidelberg). pREP4 plasmids
encoding wild-type or C95A tapasin were introduced by using
Lipofectamine 2000 (Invitrogen). pREP4 transfectants were se-
lected and maintained in 0.3 mgml Hygromycin B (Invitrogen).
Inserts were confirmed by sequencing in both directions.
Retroviral Transduction. The retroviral packaging cell line Phoe-
nix-Amphotropic (American Type Culture Collection) was
transfected on day 1 by using Effectene (Qiagen, Valencia, CA).
On day 2, cells were placed in fresh medium at 32°C. On day 3,
cell medium was centrifuged at 402  g for 5 min. Cells to be
transduced were resuspended in this supernatant with 5 gml
polybrene (Sigma) and 25 mM Hepes and centrifuged at 1,118
g for 2 h at 32°C. Thereafter, cells were incubated at 37°C and
resuspended in fresh medium the next day.
Flow Cytometry. Suspension cells were plated overnight at 3  105
cells per ml. Adherent cells were used at 50–70% confluency and
trypsinized on ice. Cells were immediately transferred to 4°C to
minimize loss of fast-decaying peptides, washed in fluorescence-
activated cell sorting (FACS) wash (PBS2% FCS0.02% NaN3),
and incubated in a saturating concentration of 1° antibody for 40
min. Cells were washed twice and resuspended in fluorescein-
labeled goat anti-mouse IgG (Sigma) or phycoerythrin-labeled goat
anti-mouse IgG (Abcam) for 30 min. Cells were washed three times
and analyzed on a FACScan flow cytometer (Becton Dickinson) by
using CELLQUEST software. Data were collected for a minimum of
10,000 cells, and live cells were gated by forward and side scatter.
Peptide Binding Experiments. Cells were incubated overnight at 26°C
in a CO2 incubator at 0.5  106 cells per ml in R10. After washing
twice at 26°C in serum-free RPMI medium 1640, cells were pulsed
with peptide for 1 h at the same temperature. For dose–response
curves, cells were prepared for flow cytometry by rapidly cooling to
4°C and incubating with 20 gml antibody (25.D1 or Y3) for 45
min followed by phycoerythrin-conjugated goat-anti-mouse Ig for
30 min. To evaluate complex half-life, peptide-pulsed cells were
warmed to 37°C, and aliquots were removed at various times,
cooled to 4°C, and prepared for flow cytometry as above.
Immunoblotting. Cells were treated with 20 mM N-ethylmaleimide
in PBS on ice for 10 min and then lysed in 0.5% Nonidet P-40 in
lysis buffer (150 mM NaCl5 mM EDTA20 mM Tris-HCl2 mM
PMSF2 mM iodoacetic acid, pH 7.4). Postnuclear supernatants
were boiled with 4 loading buffer and run on a nonreducing 8%
gel. Proteins were transferred electrophoretically to Hybond-C
extra membrane (Amersham Pharmacia), which was then blocked
with PBS2.5% fat-free milk for 1 h. The 1° antibody in PBS with
0.05% Tween 20 (PBST), and 2.5% fat-free milk was added for 1 h.
The membrane was washed three times with PBST and incubated
with horseradish peroxidase-conjugated 2° antibody for 1 h. The
membrane was washed four times with PBST, developed with
SuperSignal West Pico chemiluminescent substrate (Pierce), and
imaged with a Fluor-S MultiImager (Bio-Rad).
Immunoprecipitation. Cells were starved in MetCys-free medium
for 30 min and labeled with 35S-MetCys (Amersham Pharmacia)
for 30 min before lysis with 1% 3-[(3-cholamidopropyl)di-
methylammonio]-1-propanesulfonate (CHAPS) in lysis buffer con-
taining 10 g of 148.3 (TAP1). Postnuclear supernatants were
immunoprecipitated with protein A-Sepharose beads for 1 h. The
beads were washed three times with 0.1% CHAPS lysis buffer and
then incubated in 1% Triton X-100 lysis buffer for 30 min. The
beads were spun out, and the supernatant was added to 10g of Y3
(Kb) and fresh beads. After 1 h, beads were washed three times in
0.1% Triton X-100 lysis buffer and boiled in 25 l of SDS loading
buffer, and supernatant was run on a 10% polyacrylamide gel. The
gel was fixed, placed in Amplify (Amersham Pharmacia) for 30 min,
and dried before exposure on a PhosphorImager screen (Fuji). The
screen was imaged with a Fluor-S MultiImager.
Results
Generating a Peptide Hierarchy to Sample the MHC Class I Peptide
Repertoire. To sample the class I peptide repertoire, we generated
a single detection system with which we could analyze presentation
of peptides with a wide range of binding affinities to class I. The use
of a single detection system avoided the obfuscation of phenotypic
differences between T cells responding to epitopes of different
dominance (25). We chose flow cytometry with an MHC-peptide-
specific antibody as our readout because of its quantitative signal
over a wide range of presentation levels and its independence of
costimulation (20). A hierarchy based on the H2-Kb-binding pep-
tide SIINFEKL (chicken ovalbumin residues 257–264) was gener-
ated by varying anchor residues to produce peptides with a wide
range of binding affinities. Peptides were expressed stably as
minigenes in the cytosol, and peptide presentation was detected by
flow cytometry with the antibody 25-D1.16 (D1) (20), which could
recognize all of the peptide variants.
Peptides that bind to and stabilize Kb generally have an
aromatic residue at P5 (Tyr or Phe) and a small hydrophobic
residue at the C terminus (Leu, Met, Ile, or Val) (11, 26). To
generate suboptimal variants of SIINFEKL with a reduced
ability to stabilize Kb, peptides with substitutions at P5 and P8
were synthesized. The half-life for dissociation of these peptides
from Kb at the cell surface was determined as a relative measure
of peptide binding. TAP-deficient cells were loaded with peptide
for 1 h, peptide was washed away from the medium, and the loss
of Kb from the cell surface was observed as the peptide disso-
Fig. 1. Establishing a hierarchy of peptides based on binding quality. (a)
Half-life of Kb:SIINFEKL (}), SIINFEKV (Œ), SIINFEKM (), and SIINYEKL (F)
complexes and empty molecules () on peptide-loaded RMA-S cells is ex-
pressed as median fluorescence intensity (MFI) after flow cytometry with Y3.
The stabilization produced by the peptide at time 0 is 100%, and 0% is the
stabilization in the absence of peptide. (b) Affinity of D1 for Kb–peptide
complexes. .220 Kb tapasin cells endogenously expressing the SIINFEKL vari-
ants were incubated with D1 for 4 h at 4°C. After one wash in FACS wash, they
were resuspended in 200 l of phycoerythrin-labeled 2° antibody for 30 min
at 4°C. After one wash in FACS wash, samples were analyzed by flow cytom-
etry. (c) Binding of SIINFEKL derivatives to Kb at the cell surface of .220Kb
measured with Mab 25.D1. (d) Binding of SIINFEKL derivatives to Kb at the cell
surface of RMA-S measured with Mab Y3.
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ciated over time (Fig. 1a). SIINFEKL (variants at anchor
positions 5 or 8 are indicated in boldface) had the slowest
half-time for dissociation (360 min), SIINFEKV was faster (294
min), followed by SIINFEKM (270 min), then SIINYEKL, which
was significantly faster (120 min). The half-life of Kb, stabilized
by low temperature alone (27), was 48 min. This assay for bind-
ing therefore established the following hierarchy of peptides:
SIINFEKL  SIINFEKV  SIINFEKM  SIINYEKL.
This hierarchy spanned the range from one of the highest
reported affinities (28) to binding that is poorly detectable. Thus,
use of this hierarchy of four peptides could allow monitoring of
changes in the presentation of peptides that span a broad
spectrum of quality.
To test whether the SIINFEKL variants were recognized
equally well by 25.D1, we measured the half-maximal antibody
concentration for staining cells that endogenously expressed the
peptide variants (Fig. 1b). D1 detected all of the peptide variants.
The half-maximal concentration was equivalent for SIINFEKL,
SIINFEKV, and SIINFEKM (1 gml) but was higher for
SIINYEKL (3.5 gml). All subsequent staining with D1 was
performed at 20 gml to ensure saturation of complexes of Kb
bound to each peptide variant.
Interestingly, when we estimated the relative binding of the
peptides to Kb by their ability to stabilize Kb at the cell surface
of TAP-deficient cell lines, we observed little difference between
them. This was true regardless of whether Kb was assembled with
human (Fig. 1c) or murine (Fig. 1d) 2m.
This peptide hierarchy was introduced into cells as minigenes
by using transduction with a replication-incompetent retroviral
vector, which allowed up to 75% of cells to be stably expressing
the minigene within 2 days. A marker gene, NGFR, was driven
from the same promoter as the peptide minigene, via an internal
ribosome entry site. This marker gene served as a control that
cells expressed equivalent amounts of each peptide and allowed
transduced cells to be purified to homogeneity. Marker gene
expression for the different constructs was equivalent within all
hierarchies compared in this study (Table 1). The peptide
FILKSINE, which lacks anchor residues for Kb, was included as
a negative control for the effect of retroviral transduction.
The Effect of Tapasin on the Peptide Repertoire. Tapasin seems to
have a key role in the loading of class I with peptide (10). In the
absence of tapasin, class I is inefficiently loaded with peptide and
decays rapidly from the cell surface. We tested whether our
method of analyzing the peptide repertoire would detect differ-
ences in the presentation of peptides of different qualities when
tapasin was absent.
The peptide hierarchy described above was introduced into the
tapasin-deficient cell line .220 Kb (Fig. 2b and Table 1) or .220 Kb
transfected with tapasin (Fig. 2a and Table 1), and peptide pre-
sentation was determined by flow cytometry. All peptides were
presented to a greater extent in the presence of tapasin, and their
relative presentation followed the hierarchy of peptide binding:
SIINFEKL  SIINFEKV  SIINFEKM  SIINYEKL. However,
Table 1. Mean fluorescence intensity of staining for specific
Kb:SIINXEKX complexes with Mab 25.D1, total Kb with Mab Y3,
and truncated NGF receptor with anti-NGFR for .220-Tpn
(tapasin/) and .220 (tapasin/) transfected with minigenes
encoding SIINFEKL-related peptides
25.D1 Y3 Anti-NGFR
Peptide .220-Tpn .220 .220-Tpn .220 .220-Tpn .220
SIINFEKL 1,213 31 1,081 1,023 512 481
SIINFEKV 722 32 1,032 1,019 527 470
SIINFEKM 604 72 1,075 1,125 469 482
SIINYEKL 16 5 1,031 993 450 420
FILKSINE 4 1.6 1,120 1,113 522 438
Fig. 2. The effect of tapasin on presentation of the hierarchy. Expression level of the SIINFEKL variants in .220Kb-Tpn (a) and .220Kb (b) was determined by flow
cytometry using Mab 25.D1. (c) Hierarchy of presentation of the SIINFEKL variants with and without tapasin, expressed as a percentage of SIINFEKL presentation:
(peptide MFI FILKSINE MFI)(SIINFEKL MFI FILKSINE MFI) 100. FILKSINE MFI represents background staining. Means of duplicate measurements are shown
1 SD. Where error bars are not seen, they are too small to be obvious. (d) Correlation between the enhancement of presentation by tapasin and peptide half-life:
enhancement of presentation by tapasin, calculated as (peptide MFI FILKSINE MFI) with tapasin(peptide MFI FILKSINE MFI) without tapasin. Peptide half-life
is from Fig. 1a.
Howarth et al. PNAS  August 10, 2004  vol. 101  no. 32  11739
IM
M
U
N
O
LO
G
Y
in the absence of tapasin, this hierarchy was lost and a new one
emerged: SIINFEKM  SIINFEKL  SIINFEKV  SIINYEKL
(Fig. 2c). In the absence of tapasin, presentation of the medium-
affinity peptide SIINFEKM was dominant, and presentation of
SIINFEKV was similar to the highest affinity variant SIINFEKL.
Despite the low stability of SIINYEKL, its presentation was
clearly detectable, but in tapasin-competent cells it was 100-
fold less than that of SIINFEKL. Presentation of SIINYEKL was
also the lowest in the series in the absence of tapasin. However,
its presentation as a fraction of SIINFEKL presentation was
increased 10-fold in the absence of tapasin, supporting a role
for tapasin in editing out poor-binding peptides.
Little change was observed in total Kb expression between
different transfectants (Table 1), and Y3 staining of .220Kb and
.220Kb-Tpn was roughly equivalent. Thus, 25.D1 staining was an
indirect measurement of the fraction of Kb molecules at the cell
surface occupied by a SIINXEKX-related peptide.
The enhancement of presentation of each peptide in cells ex-
pressing tapasin varied greatly depending on the identity of the
peptide (Fig. 2c). Importantly, this enhancement correlated spe-
cifically with Kb:SIINXEKX half-life, which is probably influenced
principally by peptide off-rate (Fig. 2d) and not with peptide affinity
measured at equilibrium (Fig. 1 c and d). Tapasin only enhanced
to a small extent presentation of the poor stabilizing peptide
SIINYEKL. However, as the half-life increased, the enhancement
increased dramatically. Thus, a small increase in half-life of a
peptide, from SIINFEKV to SIINFEKL, produced a marked
increase in the effect of tapasin on its presentation.
The same relationship between peptide half-life and degree of
tapasin-mediated enhancement of presentation was seen when
the minigenes were transfected into mouse fibroblasts lacking
tapasin (a gift from L. Van Kaer, Vanderbilt University, Vander-
bilt, TN) compared to equivalent transfections into wild-type
C57BL6 fibroblasts (data not shown).
The Effect of Calreticulin on the Peptide Repertoire. Calreticulin is an
ER chaperone that interacts with heavy chain only when it is
bound to 2m (9). In calreticulin-deficient cells, class I traffics
rapidly from the ER, presents endogenous viral antigens poorly,
and has 70% reduced surface expression of class I (29).
The peptide hierarchy was introduced into wild-type and
calreticulin-deficient cells, and the presentation at the cell
surface was determined (Fig. 3 A and B). In wild-type cells, the
hierarchy followed peptide half-life: SIINFEKL SIINFEKV
SIINFEKM  SIINYEKL. In calreticulin-knockout cells, the
presentation of all of the peptides was reduced. However, unlike
with tapasin, in the absence of calreticulin the presentation of
each peptide was reduced by a similar amount. Thus, in the
absence of calreticulin, the medium-affinity peptides SIINFEKV
and SIINFEKM were still presented at approximately half the
level of the high-affinity SIINFEKL. The similar peptide hier-
archy in the presence and absence of calreticulin (Fig. 3C) is
consistent with the similar rate of decay of bulk Kb from the cell
surface in the presence or absence of calreticulin, as determined
with Brefeldin A (data not shown).
The expression of mouse or human 2m does not change
peptide presentation significantly, as indicated by (i) the similar
peptide hierarchy in wild-type mouse fibroblasts (Fig. 3C) and
.220 Kb-Tpn (Fig. 2c) and (ii) the same rate of decay of an
individual peptide, SIINFEKM, from the surface of these two
cell types (data not shown).
The Effect of ERp57 on the Peptide Repertoire. Class I is believed to
assemble with a high-affinity peptide cargo in a complex with
TAP, tapasin, calreticulin, and ERp57. Whereas the roles of
TAP, tapasin, and calreticulin have been tested by knocking out
the respective genes (14, 15, 29, 30), there is currently no system
where ERp57 expression has been down-regulated. ERp57 has
been recently shown to form a disulfide bond with tapasin, whose
formation is blocked by the C95A point mutation in tapasin (31).
Dick et al. showed that C95A tapasin allows apparently normal
assembly of heavy chain-2m with TAP, tapasin, and calreticu-
lin, but ERp57 is not recruited to this complex. We analyzed the
peptide repertoire of cells expressing the C95A mutant tapasin,
which lack ERp57 function in the peptide loading complex.
By immunoblotting for the tapasin-ERp57 covalent interme-
diate, we first confirmed that the C95A mutation stopped
formation of a disulfide to ERp57 in our cells (Fig. 4a).
Surprisingly, C95A tapasin restored the hierarchy based on
peptide affinity that was lost in the absence of tapasin (Fig. 4 b
and c). The degree of enhancement of presentation of each
peptide variant by C95A tapasin was comparable to the en-
hancement by wild-type tapasin. Thus, tapasin in the absence of
ERp57 was still able to selectively enhance the presentation of
high-affinity peptides. The lack of an effect on the peptide
hierarchy was supported by a similar rate of decay of Kb from the
cell surface with wild-type or C95A tapasin (data not shown).
The Peptide Hierarchy for a Mutant Class I That Fails to Associate with
TAP. Having established that tapasin modulates the peptide reper-
toire, we tested whether that was a result of tapasin’s effect on TAP
or a direct effect on loading of class I with peptide. Thus, we
introduced the hierarchy into cells which did express tapasin (.220
tapasin) but expressed a mutant form of class I that was unable to
associate with the peptide loading complex. The T134K mutation
in HLA-A2 stops class I interacting with the peptide loading
complex, and this leads to fast exit of poorly loaded complexes from
the ER (16). The interaction between TAP and class I was also
disrupted by the T134K mutation in Kb (Fig. 5a). When the peptide
Fig. 3. The effect of calreticulin on presentation of the hierarchy. (A)
Presentation of the SIINFEKL variants on wild-type fibroblasts was determined
by flow cytometry with D1. (B) Presentation of the SIINFEKL variants on
calreticulin-knockout fibroblasts was determined by flow cytometry with D1.
(C) Hierarchy of presentation with and without calreticulin, expressed as a
percentage of SIINFEKL presentation.
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series was introduced into .220-Tpn-T134K Kb, a hierarchy based on
peptide affinity was not observed (Fig. 5b). In fact, the pattern in
these cells was similar to that observed for .220 Kb (Fig. 2b), with
highest presentation of the medium-affinity SIINFEKM and a high
percentage of presentation of the low-affinity SIINYEKL relative
to SIINFEKL (Fig. 5c). This reinforces the idea that the effect of
tapasin on the hierarchy depends on class I directly interacting with
the peptide loading complex and is consistent with an editing
function for tapasin.
Discussion
We have established a hierarchy of peptides spanning a wide
range of half-life that we used as indicators of the repertoire of
peptides presented by class I. In tapasin-competent cells, a
hierarchy was obtained with greatest presentation of the most
stably bound peptide and reduced presentation of peptide
variants with shorter half-lives. However, in tapasin-deficient
cells, this hierarchy disappeared, and presentation was greatest
for a peptide with an intermediate half-life. Because we could
detect very little difference in binding of each of the peptides to
Kb when measured close to equilibrium conditions, we conclude
that the enhancing effect that tapasin has on peptide presenta-
tion correlates specifically with complex half-life (which is
probably influenced principally by peptide off-rate) and not with
peptide affinity per se. These data are relevant to a recent report
by Zarling et al. (32), who observed no difference in the average
affinity of peptides eluted from HLA-B8 assembled in normal
versus tapasin-incompetent cells, despite a significant difference
in the cell-surface half-life of B8 in these two cells and argued
that their data support a peptide–class I complex-stabilizing
function for tapasin. Contrary to this report, we have found the
same rate of decay of an endogenously synthesized individual
peptide, SIINFEKM, from the surface of these two cell-types
(data not shown). The present data show that peptide affinity
measurements and cell-surface half-life measurements are not
necessarily concordant; therefore, the repertoire of peptides
eluted from HLA-B8 assembled in .220 by Zarling et al. may in
fact have a shorter half-life than the repertoire eluted from B8
made in .220-Tpn; hence, differences in repertoire may still have
arisen as a result of tapasin-mediated peptide editing.
Analyzing tapasin-deficient cells alone is insufficient to re-
solve the importance of tapasin because, in the absence of
tapasin, class I generally fails to interact with ERp57, TAP, and
calreticulin (9). However, here we have also explored the peptide
hierarchy in calreticulin-deficient cells and cells where ERp57 is
not recruited to TAP. The hierarchy of peptides is not greatly
changed by the absence of calreticulin, which suggests that it is
the interaction between class I and tapasin that is essential for
changing the peptide repertoire, and this interaction can still
occur in the absence of calreticulin (29). The decrease in surface
expression levels in the absence of calreticulin is more likely to
reflect increased export in calreticulin-deficient cells of class I
free of peptide. Failure to recruit ERp57 to TAP also has little
Fig. 4. The effect of recruiting ERp57 to the TAP on presentation of the
hierarchy. (a) .220Kb(tpn/) was transfected with wild-type (WT) or C95A
mutant tapasin, and aliquots of cells were incubated with N-ethylmaleimide.
Lysates were fractionated by SDSPAGE and blotted with antitapasin. A band
corresponding to disulfide-bonded heterodimers of ERp57 and tapasin was
only seen in cells expressing WT tapasin. (b) Peptide presentation on .220Kb,
.220Kb-Tpn, or .220Kb C95A tapasin was determined by flow cytometry with
D1, and the MFI is displayed. Data for SIINFEKV were not obtained. (c)
Hierarchy of presentation with WT or C95A mutant tapasin, expressed as a
percentage of SIINFEKL presentation.
Fig. 5. The effect of the T134K mutation on presentation of the hierarchy.
(a) The effect of the T134K mutation in Kb on TAP association. 35S-MetCys-
labeled anti-TAP coimmunoprecipitates (148.3) from .220 Kb tapasin or .220
T134K Kb tapasin cells were released by Triton X-100 and reprecipitated with
Y3 (Upper). An aliquot of postnuclear supernatant was immunoblotted for
calreticulin as a control for equal cell number (Lower). (b) Level of presenta-
tion of the SIINFEKL variants with a T134K mutation in Kb. Peptide presenta-
tion on .220 T134K Kb tapasin was determined by flow cytometry with D1.
SIINFEKV presentation was not determined. (c) Hierarchy of presentation of
the SIINFEKL variants with a T134K mutation in Kb, expressed as a % of
SIINFEKL presentation. Means of duplicate measurements are shown 1 SD.
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effect on the extent or hierarchy of peptide loading for Kb,
pointing to the preeminence of tapasin in the action of the
peptide loading complex to optimize peptide loading. Although
we do not exclude the possibility that ERp57 molecules not
bound to tapasin might have a function in modulating the
peptide repertoire, we show that recruitment of ERp57 to TAP
is not essential for normal loading of Kb with peptide.
This study provides a clear indication of a reshaping of the
peptide repertoire in the presence of tapasin and shows that
the presentation of peptides at the cell surface, which relates to
the level of T cell priming, depends on the degree of optimization
of class I-bound peptides in the ER.
Having established that tapasin is the key chaperone in control
of peptide loading quality, we must ask how tapasin carries out its
quantitative and qualitative effects. The first critical effect is on
TAP function. Tapasin both stabilizes TAP expression and bridges
class I to TAP (10). Enhancing the TAP level would explain why all
of the peptides are presented better in the presence of tapasin, but
not why presentation of high-affinity peptides was preferentially
enhanced by tapasin. Tapasin expression does not change the
peptide selectivity of TAP (10, 33). Also, when we expressed, in
the presence of tapasin, a form of Kb that did not interact with the
peptide loading complex, the hierarchy was equivalent to wild-type
Kb in the absence of tapasin.
A second suggested role of tapasin is to retain poorly loaded
class I molecules in the ER. However, retention is not tapasin’s
principal mode of action because tapasin has no effect on
retention of some alleles but still improves their peptide loading
(34). Also, retaining Kb from tapasin-deficient cells in the ER
with Brefeldin A for 4 h and then allowing Kb to traffic to the
cell surface did not restore the peptide hierarchy found in the
presence of tapasin (data not shown), confirming that retention
does not explain the effects of tapasin that we observed.
A third role of tapasin is as a catalyst for peptide loading (a
loadase function). Key evidence for this comes from work on
H2-M3 and HLA-G, where in the absence of tapasin, even when
high levels of peptide are supplied, peptide loading is inefficient
(35–37). Our results indicate that the loadase activity is greater
for optimal peptides, i.e., those that enjoy a long half-life at the
cell surface and are therefore most likely to be immunodominant
(38). Low-affinity peptides such as SIINYEKL may bind to class
I, but tapasin may stabilize a conformation of class I from which
the dissociation of suboptimal peptides is enhanced relative to
that of suboptimal sequences (39). Overall, the analogy between
the loading function of tapasin and HLA-DM is supported by our
study and echoes the observation that HLA-DM can reduce
presentation by class II of cryptic epitopes and enhance presen-
tation of immunodominant epitopes (40).
The great majority of studies of class I antigen presentation have
analyzed high-affinity peptides, so the study here of the presenta-
tion of SIINYEKL is of importance. Detection of such low-affinity
peptides is vital because of their significance as tumor antigens and
in autoimmune disease, as they are less likely to induce negative
selection of responding T cells (41). The bearing of our results on
immunodominance should also be considered, as the hierarchy of
binding strength of the peptides used in this study also represents
a hierarchy of immunogenicity (42). Our results indicate that
changes in tapasin expression, as occurs with certain viruses (43, 44)
and tumors (45), could change dominance hierarchies and thus help
determine the success or failure of the immune response.
We thank A. Kontouli for excellent technical assistance. This work was
supported by the Medical Research Council (M.H.) and the Wellcome
Trust (T.E.).
1. Shastri, N., Schwab, S. & Serwold, T. (2002) Annu. Rev. Immunol. 20, 463–493.
2. Engelhard, V. H., Brickner, A. G. & Zarling, A. L. (2002) Mol. Immunol. 39, 127–137.
3. Madden, D. R. (1995) Annu. Rev. Immunol. 13, 587–622.
4. Williams, A., Peh, C. A. & Elliott, T. (2002) Tissue Antigens 59, 3–17.
5. Ortmann, B., Copeman, J., Lehner, P. J., Sadasivan, B., Herberg, J. A.,
Grandea, A. G., Riddell, S. R., Tampe, R., Spies, T., Trowsdale, J. & Cresswell,
P. (1997) Science 277, 1306–1309.
6. Hughes, E. A. & Cresswell, P. (1998) Curr. Biol. 8, 709–712.
7. Lindquist, J. A., Jensen, O. N., Mann, M. & Hammerling, G. J. (1998) EMBO
J. 17, 2186–2195.
8. Morrice, N. A. & Powis, S. J. (1998) Curr. Biol. 8, 713–716.
9. Sadasivan, B., Lehner, P. J., Ortmann, B., Spies, T. & Cresswell, P. (1996)
Immunity 5, 103–114.
10. Momburg, F. & Tan, P. (2002) Mol. Immunol. 39, 217–233.
11. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. (1991)
Nature 351, 290–296.
12. Cerundolo, V., Elliott, T., Elvin, J., Bastin, J., Rammensee, H. G. & Townsend,
A. (1991) Eur. J. Immunol. 21, 2069–2075.
13. Brocke, P., Garbi, N., Momburg, F. & Hammerling, G. J. (2002) Curr. Opin.
Immunol. 14, 22–29.
14. Grandea, A. G., III, Golovina, T. N., Hamilton, S. E., Sriram, V., Spies, T.,
Brutkiewicz, R. R., Harty, J. T., Eisenlohr, L. C. & Van Kaer, L. (2000)
Immunity 13, 213–222.
15. Garbi, N., Tan, P., Diehl, A. D., Chambers, B. J., Ljunggren, H. G., Momburg,
F. & Hammerling, G. J. (2000) Nat. Immunol. 1, 234–238.
16. Lewis, J. W., Neisig, A., Neefjes, J. & Elliott, T. (1996) Curr. Biol. 6, 873–883.
17. Barnden, M. J., Purcell, A. W., Gorman, J. J. & McCluskey, J. (2000)
J. Immunol. 165, 322–330.
18. Tan, P., Kropshofer, H., Mandelboim, O., Bulbuc, N., Hammerling, G. J. &
Momburg, F. (2002) J. Immunol. 168, 1950–1960.
19. Barber, L. D., Howarth, M., Bowness, P. & Elliott, T. (2001) Tissue Antigens 58,
363–368.
20. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. (1997)
Immunity 6, 715–726.
21. Greenwood, R., Shimizu, Y., Sekhon, G. S. & DeMars, R. (1994) J. Immunol.
153, 5525–5536.
22. Mesaeli, N., Nakamura, K., Zvaritch, E., Dickie, P., Dziak, E., Krause, K. H.,
Opas, M., MacLennan, D. H. & Michalak, M. (1999) J. Cell Biol. 144, 857–868.
23. Tolstrup, A. B., Duch, M., Dalum, I., Pedersen, F. S. & Mouritsen, S. (2001)
Gene 263, 77–84.
24. Duch, M., Tolstrup, A., Dalum, I., Jespersen, T., Mouritsen, S. & Pedersen,
F. S. (1999) BioTechniques 26, 1032–1036.
25. Spencer, J. V. & Braciale, T. J. (2000) J. Exp. Med. 191, 1687–1698.
26. Udaka, K., Wiesmuller, K. H., Kienle, S., Jung, G., Tamamura, H., Yamagishi,
H., Okumura, K., Walden, P., Suto, T. & Kawasaki, T. (2000) Immunogenetics
51, 816–828.
27. Ljunggren, H. G., Stam, N. J., Ohlen, C., Neefjes, J. J., Hoglund, P., Heemels,
M. T., Bastin, J., Schumacher, T. N., Townsend, A., Karre, K., et al. (1990)
Nature 346, 476–480.
28. Kageyama, S., Tsomides, T. J., Sykulev, Y. & Eisen, H. N. (1995) J. Immunol.
154, 567–576.
29. Gao, B., Adhikari, R., Howarth, M., Nakamura, K., Gold, M. C., Hill, A. B.,
Knee, R., Michalak, M. & Elliott, T. (2002) Immunity 16, 99–109.
30. Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L. & Tonegawa, S. (1992) Cell
71, 1205–1214.
31. Dick, T. P., Bangia, N., Peaper, D. R. & Cresswell, P. (2002) Immunity 16, 87–98.
32. Zarling, A. L., Luckey, C. J., Marto, J. A., White, F. M., Brame, C. J., Evans,
A. M., Lehner, P. J., Cresswell, P., Shabanowitz, J., Hunt, D. F. & Engelhard,
V. H. (2003) J. Immunol. 171, 5287–5295.
33. Bangia, N., Lehner, P. J., Hughes, E. A., Surman, M. & Cresswell, P. (1999) Eur.
J. Immunol. 29, 1858–1870.
34. Lewis, J. W., Sewell, A., Price, D. & Elliott, T. (1998) Eur. J. Immunol. 28,
3214–3220.
35. Park, B. & Ahn, K. (2003) J. Biol. Chem. 278, 14337–14345.
36. Lybarger, L., Yu, Y. Y., Chun, T., Wang, C. R., Grandea, A. G., III, Van Kaer,
L. & Hansen, T. H. (2001) J. Immunol. 167, 2097–2105.
37. Chun, T., Grandea, A. G., III, Lybarger, L., Forman, J., Van Kaer, L. & Wang,
C. R. (2001) J. Immunol. 167, 1507–1514.
38. Yewdell, J. W. & Bennink, J. R. (1999) Annu. Rev. Immunol. 17, 51–88.
39. Springer, S., Doring, K., Skipper, J. C., Townsend, A. R. & Cerundolo, V.
(1998) Biochemistry 37, 3001–3012.
40. Nanda, N. K. & Sant, A. J. (2000) J. Exp. Med. 192, 781–788.
41. Fairchild, P. J. & Wraith, D. C. (1996) Immunol. Today 17, 80–85.
42. Lipford, G. B., Bauer, S., Wagner, H. & Heeg, K. (1995) Vaccine 13, 313–320.
43. Bennett, E. M., Bennink, J. R., Yewdell, J. W. & Brodsky, F. M. (1999)
J. Immunol. 162, 5049–5052.
44. Vertegaal, A. C., Kuiperij, H. B., Houweling, A., Verlaan, M., van der Eb, A. J.
& Zantema, A. (2003) J. Biol. Chem. 278, 139–146.
45. Dissemond, J., Kothen, T., Mors, J., Weimann, T. K., Lindeke, A., Goos, M.
& Wagner, S. N. (2003) Arch. Dermatol. Res. 295, 43–49.
11742  www.pnas.orgcgidoi10.1073pnas.0306294101 Howarth et al.
